Here are the G-BA decisions from the G-BA meeting held on 16 November 2023 on the early benefit assessments of Breyanzi and Tecartus.
A complete database of all previous G-BA resolutions is available through my membership.
- Breyanzi (lisocabtagene maraleucel); new indication: Diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, after 1 previous therapy, relapse within 12 months or refractory – Hint of considerable additional benefit in one of three subgroups
- Tecartus (autologous anti-CD19-transduced CD3-positive cells); relapsed or refractory mantle cell lymphoma – Request for RWE collection, change of comparator; Re-assessment starting 21 July 2028
Follow me on Instagram to never miss the latest G-BA decisions: